(2023). Glucose-lowering treatment pathways of individuals with chronic kidney disease and type 2 diabetes according to the Kidney Disease: Improving Global Outcomes 2012 risk classification. Diabet Med, e15200. http://doi.org/10.1111/dme.15200.
(2022). Healthcare resource utilisation and related costs of patients with CKD from the UK: a report from the DISCOVER CKD retrospective cohort. Clin Kidney J, 15, 2124-2134. http://doi.org/10.1093/ckj/sfac168.
(2022). Low Adherence to Kidney Disease: Improving Global Outcomes 2012 CKD Clinical Practice Guidelines Despite Clear Evidence of Utility. Kidney Int Rep, 7, 2059-2070. http://doi.org/10.1016/j.ekir.2022.05.033.
(2020). Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med. http://doi.org/10.1186/s12916-020-01659-x.